Navigation Links
Odyssey Thera is First to Install Next Generation High-Content Imaging Capability
Date:11/29/2011

SAN RAMON, Calif., Nov. 29, 2011 /PRNewswire/ -- Odyssey Thera, Inc., a technology provider focused on deciphering biologically-relevant pathways in human cells, announced today that it has installed the IN Cell Analyzer 6000, a laser-based confocal imaging platform from GE Healthcare, to advance the world's largest high-content assay capability.

Odyssey Thera applies a systems biology approach to advance knowledge of the complex cellular networks responsible for biologically–relevant pathway activity. The company has advanced proprietary, cell-based technologies including protein-fragment complementation assays (PCAs) that allow protein-protein complexes to be precisely imaged and localized within live cells.

Using PCA and other technologies, Odyssey has created the world's largest high-content assay capability. Fully-integrated hardware, software and IT infrastructure enables very high throughput, creating a unique systems- and chemical-biology platform capable of capturing and analyzing hundreds of thousands of microscopic images per day.

The IN Cell Analyzer 6000 employs a unique optical engine combined with a next generation sCMOS detector to support high-throughput and high-resolution imaging of diverse biological events. In contrast to conventional fixed aperture confocal systems, the proprietary IN Cell Analyzer 6000 optical system features a fully adjustable variable aperture for increased flexibility.

"The IN Cell 6000 is designed for the most demanding high-content cellular applications, including live cell assays, 3D imaging, co-localization studies and imaging of assays with low signal. The choice of GE Healthcare's IN Cell 6000 reflects Odyssey's goal of maintaining our leadership position in highly contextual cellular analysis," said John K. Westwick, Ph.D., President and CEO of Odyssey Thera.

"The Odyssey team will use the IN Cell 6000 for multiple projects, including advancement of partner drug discovery programs and collaborative work with the United States Environmental Protection Agency (EPA), in which methods are being developed to improve detection of environmental toxicants," said Jane E. Lamerdin, Ph.D., Executive Director of R&D at Odyssey Thera.

About Odyssey Thera

Odyssey Thera, Inc. is a privately held biotechnology company based in San Ramon, California. The company is a leading developer of enabling technologies focused on deciphering biologically-relevant pathways in living human cells to improve the process of target and drug discovery and to advance methods for environmental chemical toxicity assessment. Patents owned by Odyssey Thera cover the use of the PCA technology in human cells, live animals, plants, diagnostic and biomarker, bioprocess, biodefense, and environmental applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
2. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
3. Odyssey Thera Announces U.S. Patent for Technologies Enabling Protein Interaction Screening and Directed Evolution
4. Odyssey Thera to Participate in Expanded EPA Initiative
5. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
6. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
7. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
8. Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test for an Additional Investigational Cancer Immunotherapy Antigen
9. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
10. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
11. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017  Directors from Pharma To Market Pty Ltd and ... forces, resulting in the founding of Pharma To Market Pte Ltd, ... Market are pleased to announce their expansion into Asia ... Singapore . The company are delighted to appoint Joelle ... Singapore based entity. Joelle brings with her ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... Miami, Florida (PRWEB) , ... February 26, 2017 ... ... disease (PD) patients after receiving cognitive rehabilitation, according to a study released today ... already known that cognitive rehabilitation programs are proven to be effective in improving ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... 24, 2017 , ... WHAT: , The New Jersey Tech ... well as advocacy for the state and region‘s technology businesses, hosted their 2017 ... Council's Innovation Forecast event highlights innovation throughout the region from small to large ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is here, and ... that 47 percent of all jobs in the United States may be taken over ... day of the aggressive know-it-all who steamrolls over colleagues is drawing to a close. ...
Breaking Medicine News(10 mins):